NCT03038672 2025-11-10
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
University of California, San Francisco
Celldex Therapeutics